Subtyping non-small cell lung cancer by histology-guided spatial metabolomics

Neumann JM, Freitag H, Hartmann J, Niehaus K, Galanis M, Griesshammer M, Kellner U, Bednarz H (2021)
Journal of Cancer Research and Clinical Oncology 148(3): 351–360.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA 6.67 MB
Autor*in
Neumann, Judith MarthaUniBi; Freitag, Hinrich; Hartmann, Jasmin ; Niehaus, KarstenUniBi; Galanis, Michail; Griesshammer, Martin; Kellner, Udo; Bednarz, HannaUniBi
Abstract / Bemerkung
Purpose Most cancer-related deaths worldwide are associated with lung cancer. Subtyping of non-small cell lung cancer (NSCLC) into adenocarcinoma (AC) and squamous cell carcinoma (SqCC) is of importance, as therapy regimes differ. However, conventional staining and immunohistochemistry have their limitations. Therefore, a spatial metabolomics approach was aimed to detect differences between subtypes and to discriminate tumor and stroma regions in tissues. Methods Fresh-frozen NSCLC tissues (n = 35) were analyzed by matrix-assisted laser desorption/ionization-mass spectrometry imaging (MALDI-MSI) of small molecules (< m/z 1000). Measured samples were subsequently stained and histopathologically examined. A differentiation of subtypes and a discrimination of tumor and stroma regions was performed by receiver operating characteristic analysis and machine learning algorithms. Results Histology-guided spatial metabolomics revealed differences between AC and SqCC and between NSCLC tumor and tumor microenvironment. A diagnostic ability of 0.95 was achieved for the discrimination of AC and SqCC. Metabolomic contrast to the tumor microenvironment was revealed with an area under the curve of 0.96 due to differences in phospholipid profile. Furthermore, the detection of NSCLC with rarely arising mutations of the isocitrate dehydrogenase (IDH) gene was demonstrated through 45 times enhanced oncometabolite levels. Conclusion MALDI-MSI of small molecules can contribute to NSCLC subtyping. Measurements can be performed intraoperatively on a single tissue section to support currently available approaches. Moreover, the technique can be beneficial in screening of IDH-mutants for the characterization of these seldom cases promoting the development of treatment strategies.
Stichworte
Non-small cell lung cancer; Adenocarcinoma; Squamous cell carcinoma; Isocitrate dehydrogenase; Mass spectrometry imaging; Metabolomics
Erscheinungsjahr
2021
Zeitschriftentitel
Journal of Cancer Research and Clinical Oncology
Band
148
Ausgabe
3
Seite(n)
351–360
ISSN
0171-5216
eISSN
1432-1335
Finanzierungs-Informationen
Open-Access-Publikationskosten wurden durch die Universität Bielefeld im Rahmen des DEAL-Vertrags gefördert.
Page URI
https://pub.uni-bielefeld.de/record/2959750

Zitieren

Neumann JM, Freitag H, Hartmann J, et al. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology. 2021;148(3):351–360.
Neumann, J. M., Freitag, H., Hartmann, J., Niehaus, K., Galanis, M., Griesshammer, M., Kellner, U., et al. (2021). Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology, 148(3), 351–360. https://doi.org/10.1007/s00432-021-03834-w
Neumann, Judith Martha, Freitag, Hinrich, Hartmann, Jasmin, Niehaus, Karsten, Galanis, Michail, Griesshammer, Martin, Kellner, Udo, and Bednarz, Hanna. 2021. “Subtyping non-small cell lung cancer by histology-guided spatial metabolomics”. Journal of Cancer Research and Clinical Oncology 148 (3): 351–360.
Neumann, J. M., Freitag, H., Hartmann, J., Niehaus, K., Galanis, M., Griesshammer, M., Kellner, U., and Bednarz, H. (2021). Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology 148, 351–360.
Neumann, J.M., et al., 2021. Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology, 148(3), p 351–360.
J.M. Neumann, et al., “Subtyping non-small cell lung cancer by histology-guided spatial metabolomics”, Journal of Cancer Research and Clinical Oncology, vol. 148, 2021, pp. 351–360.
Neumann, J.M., Freitag, H., Hartmann, J., Niehaus, K., Galanis, M., Griesshammer, M., Kellner, U., Bednarz, H.: Subtyping non-small cell lung cancer by histology-guided spatial metabolomics. Journal of Cancer Research and Clinical Oncology. 148, 351–360 (2021).
Neumann, Judith Martha, Freitag, Hinrich, Hartmann, Jasmin, Niehaus, Karsten, Galanis, Michail, Griesshammer, Martin, Kellner, Udo, and Bednarz, Hanna. “Subtyping non-small cell lung cancer by histology-guided spatial metabolomics”. Journal of Cancer Research and Clinical Oncology 148.3 (2021): 351–360.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Creative Commons Namensnennung 4.0 International Public License (CC-BY 4.0):
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2022-08-25T08:01:48Z
MD5 Prüfsumme
20b74dd6a4c90d5cf916ae7928bb1617

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®
Quellen

PMID: 34839410
PubMed | Europe PMC

Suchen in

Google Scholar